The LEADER study made liraglutide the second hypoglycemic agent after the sodium-glucose cotransporter-2 inhibitor (SGLT2i), empagliflozin, to demonstrate cardiovascular benefits in randomized clinical trials, which was a significant breakthrough and source of inspiration for cardiologists and researchers, marking a landmark in the field (Kristensen et al., 2019)
"Glutathione system enhancement for cardiac protection: pharmacological options against oxidative stress and ferroptosis." Cell Death & Disease
INSTANT COFFEE IN A STICK - Easy brewing instant coffee for you to enjoy anytime anywhere
Their effects are more often reflected in symptom improvement rather than lab results
doi: 10.1089/dia.2024.0023 26 NassarMChaudhuriAGhanimHDandonaP
In most cases, the longer the exposure, the more severe the symptoms